9 episodes

Business Trip tells the story of the emerging industry of psychedelics. Each episode features founders from biotech startups developing novel compounds, to clinics and retreats for healing, to software companies building tools to power the ecosystem.

Business Trip Greg Kubin & Matias Serebrinsky

    • Business
    • 5.0 • 25 Ratings

Business Trip tells the story of the emerging industry of psychedelics. Each episode features founders from biotech startups developing novel compounds, to clinics and retreats for healing, to software companies building tools to power the ecosystem.

    Analyzing the atai Life Sciences IPO

    Analyzing the atai Life Sciences IPO

    Today's episode features three experts, Josh Hardman, Michael Haichin, and Graham Pechenik as they analyze atai’s S-1 in advance of their IPO. 


    In this episode, we discuss:
    How atai went from idea to IPO in 3 yearsAn overview of atai’s drug development programs and enabling technologiesThe platform’s strategy and risks
    Links to topics discussed in this episode:
    Atai life sciences
    Etifoxine
    Esketamine & arketamine
    Atai’s S-1
    Psychedelic Pharmacist Association
    Calyx Law
    Psilocybin Alpha, Noetic Fund
    kratom, Salvinorin A, BNC210, mitragynine
    Mike Novogratz, Christian Angermayer, George Goldsmith, Ekaterina Malievskaia, Peter Thiel
    PureTech Health, Akili Interactive Labs
    Business Trip’s DemeRx Episode
    Viridia Life Sciences, Revixia Life Sciences, EmpathBio, Kures, Recognify Life Sciences


    Read the transcript here.
    Created by Greg Kubin and Matias Serebrinsky
    Host: Matias Serebrinsky
    Produced by Jonathan Davis & Zack Frank
    Marketing by DaisyMae VanValkenburgh
    Find us at businesstrip.fm
    Follow us on Instagram and Twitter!
    Theme music by Dorian Love
    Additional music: The Innovation by Zack Frank (our very own sound engineer!)

    • 50 min
    A 30 year journey towards ibogaine approval: Deborah Mash, CEO of DemeRx

    A 30 year journey towards ibogaine approval: Deborah Mash, CEO of DemeRx

    Today's episode features Deborah Mash, founder and CEO of DemeRx, a clinical stage company developing ibogaine therapies to treat substance use disorders.
    In this episode, we discuss:
    The science, experience and the safety behind Ibogaine’s “neurochemical reset”Navigating US drug regulatory system and securing Intellectual PropertyDeborah’s 30 journey through Amsterdam, Miami and the Caribbean aiming to get Ibogaine therapy approvedPartnership with ATAI Life SciencesLinks to topics discussed in this episode:
    Deborah Mash
    DemeRx
    Ibogaine
    Noribogaine
    Tabernanthe Iboga
    Bwiti Religion
    Howard Lotsof
    Serotonergics
    Lambarene - promoted as a mental and physical stimulant
    Habenula
    Addiction Expert Gabor Maté


    Read the transcript here.
    Watch episode 8 on YouTube.
    Created by Greg Kubin and Matias Serebrinsky
    Host: Greg Kubin
    Produced by Jonathan Davis & Zack Frank
    Marketing by DaisyMae VanValkenburgh
    Find us at businesstrip.fm
    Follow us on Instagram and Twitter!
    Theme music by Dorian Love
    Additional music by Medita by Crowander, Two Feet by Muted Circus, and Rain On Me by JBlanked.

    • 44 min
    Clinical trials, media, reciprocity, open science: Founder of The Trip Report, Zach Haigney

    Clinical trials, media, reciprocity, open science: Founder of The Trip Report, Zach Haigney

    Today's episode features Zach Haigney, creator of The Trip Report, a newsletter about psychedelics, policy and business.
    In 2019, Zach started writing The Trip Report and quickly grew his readership by analyzing psychedelic news headlines from every angle. He’s able to break through all the noise and report with a sense of fairness.
    In this episode, we discuss:
    Origin story of The Trip ReportThe complexities of clinical trialsDiversity, inclusion and reciprocity in psychedelic companiesLinks to topics discussed in this episode:
    The Trip Report
    Zach Haigney
    Oregon Measure 109 - 2020
    MAPS
    COMPASS Pathways
    Usona
    Psilocybin Alpha
    Bob Jesse - Council for Spiritual Practices
    5-HT2A
    Serotonin Syndrome
    Northstar Pledge
    Nagoya Protocol
    Free, Prior, and Informed Consent

    Read the transcript here.
    Watch episode 7 on YouTube.
    Created by Greg Kubin and Matias Serebrinsky
    Host: Greg Kubin
    Produced by Jonathan Davis & Zack Frank
    Marketing by DaisyMae VanValkenburgh

    Find us at businesstrip.fm
    Follow us on Instagram and Twitter!

    Theme music by Dorian Love
    Additional music by Sun Inside by Ketsa and Better Days Ahead by Ketsa

    • 21 min
    How to (legally) make psychedelic medicine: CEO of Psygen, Danny Motyka

    How to (legally) make psychedelic medicine: CEO of Psygen, Danny Motyka

    Today's episode features Danny Motyka, founder of Psygen, a Canadian manufacturer of psychedelics, like MDMA, LSD, DMT, and synthetic psilocybin.
    Psygen makes pharmaceutical grade psychedelic medicines for clinical research and therapeutic applications. They have a license to be one of the first manufacturing facilities dedicated to the synthesis of psychedelic medicine. 
    In this episode, we discuss:
    Behind the scenes of Psygen’s manufacturing processNatural vs Synthetic psychedelicsNavigating regulations for manufacturing Schedule 1 substancesLinks to topics discussed in this episode:
    GMP
    Dr. Peter van der Heyden
    COMP360
    Entourage Effect
    Health Canada
    Nick Sand - Orange Sunshine
    MDMA, LSD, 5-MeO-DMT, Ibogaine, Psilocybin
    Entheon Biomedical
    MAPS
    2C-B


    Read the transcript here.
    Watch episode 6 on YouTube.
    Created by Greg Kubin and Matias Serebrinsky
    Host: Greg Kubin
    Produced by Jonathan Davis & Zack Frank
    Marketing by DaisyMae VanValkenburgh


    Find us at businesstrip.fm
    Follow us on Instagram and Twitter!


    Theme music by Dorian Love
    Additional music by Crystals by Xylo-Ziko, Obscure Train by Revolution Void, Love Chances by Makaih Beats, and Kleptotonic Swing by Tri-Tachyon

    • 30 min
    From serving medicine to company founder: NANA founder Flor Bollini

    From serving medicine to company founder: NANA founder Flor Bollini

    Today's episode features Flor Bollini, founder of NANA, an online platform that guides patients on using psychedelic medicine for holistic healing.
    NANA provides personalized protocols based on an assessment of your mental, emotional and physical health. From there you are partnered with a Nana or guide who leads telemedicine therapy that incorporates ketamine, cannabis and CBD.
    Flor hopes these protocols will become best practices for patients, clinics, and the psychedelic medicine ecosystem.
    In this episode, we discuss:
    Why Flor transitioned from serving medicine to company founderDeveloping protocols where the FDA doesn’t regulateThe benefits of progressive dosingHer experiences with 5-MeO-DMT and Iboga. “The Everest of psychedelics” as she calls them.

    Links to topics discussed in this episode:
    UNESCO - United Nations Educational, Scientific and Cultural Organization
    Ifa - Ancient Divination System
    Ayurveda
    Jungian
    5-MeO-DMT
    LMS - Learning Management System
    REM Sleep - Rapid Eye Movement Sleep
    SSRIs - Selective Serotonin Reuptake Inhibitors
    Ayahuasca
    Ibogaine
    Bwiti religion
    Serotonin Syndrome

    Read the transcript here.
    Watch episode 5 on YouTube.
    Created by Greg Kubin and Matias Serebrinsky
    Host: Greg Kubin
    Produced by Jonathan Davis
    Marketing by DaisyMae VanValkenburgh


    Find us at businesstrip.fm
    Follow us on Instagram and Twitter!


    Theme music by Dorian Love
    Additional music by Blue Dot Sessions.

    • 33 min
    Helping psychedelic practitioners through software: Maya Health CEO David Champion

    Helping psychedelic practitioners through software: Maya Health CEO David Champion

    Today's episode features David Champion, CEO and co-founder of Maya, a software platform that helps practitioners and clinics manage psychedelic-assisted therapy practices. The data collected from treatments will help psychedelic stakeholders, from researchers to pharmaceutical companies, discover insights for safer and more effective treatments.
    In this episode, we discuss:
    Removing the guesswork from developing psychedelic therapy protocolsFundraising tips for psychedelic company foundersThe role of data in surfacing safer and more effective treatmentsA big announcement from Matias and Greg!Links to topics discussed in this episode:
    Zendo Project - Subsidiary of MAPS
    Johns Hopkins - Center for Psychedelic and Consciousness Research
    MAPS
    CIIS
    EMR & EHR - What's the difference?


    Read the transcript here.
    Watch episode 4 on YouTube.
    Created by Greg Kubin and Matias Serebrinsky
    Host: Greg Kubin
    Produced by Jonathan Davis
    Marketing by DaisyMae VanValkenburgh


    Find us at businesstrip.fm
    Follow us on Instagram and Twitter!


    Theme music by Dorian Love
    Additional music by Blue Dot Sessions.

    • 29 min

Customer Reviews

5.0 out of 5
25 Ratings

25 Ratings

megan@podcastingyou ,

Incredible Content!

Greg and Matias do such a good job covering a variety of topics. The guests offer valuable insight as well. I would recommend this podcast to anyone looking to be inspired and informed!

Luciacisilotto ,

Expansive!

Very interesting podcast, I really enjoyed the edge, the information given and the openness to alternative ways of healing within the field of psychotherapy. Great content to explore :)

Fred Silverstein ,

Fantastic podcast

Wonderful podcast that educates and expands the way I think about opportunities in this new domain. Can’t wait for the next episode!!’

Top Podcasts In Business

Listeners Also Subscribed To